| 摘要 |
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions refers to using an agent reducing B-cell count for treating chronic fatigue syndrome, as well as to a method of treating chronic fatigue syndrome involving the stage of administering the agent reducing B-cell count into an individual suffering from it. The agent reducing B-cell count can represent a preferentially humanised CD20 antibody reducing B-cell count or the fragment of the above CD20 binding antibody.EFFECT: using the given group of inventions based on B-cell count depletion, is effective in treating chronic fatigue syndrome.14 cl, 1 dwg, 1 ex |
